Navigation Links
Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP
Date:6/19/2013

Santa Ana, CA (PRWEB) June 19, 2013

McGuff Pharmaceuticals, Inc. continues to pursue the approval of an Abbreviated New Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple dose vial; a generic version of Bristol-Myers Squibb’s drug fomerly known as Delalutin™. We are providing this update in response to varied inquiries regarding the anticipated approval and market introduction dates for McGuff’s Hydroxyprogesterone Caproate Injection, USP drug product.

Regarding the status of our pending ANDA, to date, McGuff has responded to all Food and Drug Administration (FDA) inquiries concerning the ANDA submitted in October 2009. While we are hopeful that a final decision will be made soon, McGuff can not predict when the Agency will make it’s final determination concerning the ANDA approval. We remain committed to bringing Hydroxyprogesterone Caproate Injection, USP to market as quickly as possible.

Our commitment to bring cost effective branded and generic injectable drugs to the U.S. and International markets, for the benefit of patients in need, continues to be one of our driving principles.

If you would like more information about this topic or to schedule an interview with Damon P. Jones, Vice President of McGuff Pharmaceuticals, Inc., please contact Maureen French at 800-603-4795 x301 or email mfrench(at)mcguff(dot)com. You may also visit our website at http://www.mcguffpharmaceuticals.com.

About McGuff Pharmaceuticals, Inc.

McGuff Pharmaceuticals is a Food and Drug Administration (FDA) inspected sterile fill manufacturer that maintains a tradition of quality and core competency in both FDA current Good Manufacturing Practices (cGMP) and International Organization for Standardization’s Quality Management Systems (ISO) 9001:2008, a unique combination for any pharmaceutical manufacturer.

The McGuff family of companies provides commercial pharmaceuticals, compounded drugs, nutritional supplements, medical products and contract services used by leading healthcare organizations and professionals.

The McGuff family of companies includes:

McGuff Company, Inc. – Corporate Headquarters and Medical Products Distribution Center

Subsidiaries:

McGuff Pharmaceuticals, Inc. – Commercial drug manufacturing
McGuff Medical Canada, Inc. – Medical products distribution
McGuff Compounding Pharmacy Services, Inc. – Pharmacy and Compounded drugs

Read the full story at http://www.prweb.com/releases/2013/6/prweb10833717.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PET/MR effective for imaging recurrent prostate cancer
2. ENT and Allergy Associates®, LLP Is Bullish on Wall Street; Practice to Expand/Upgrade Current Clinical Office at 150 Broadway in NYC
3. Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies
4. Poliovirus vaccine trial shows early promise for recurrent glioblastoma
5. Hound.com Finds Jobs in South Atlantic and South West Central Regions Mirroring Current Employment Trends
6. Apple Products are Currently Marked Down at SportsFanPlayground.com
7. Seeking Damages From Bullies: New Website, Bullying Decoded, Reviews Current Legal Cases and Statutes
8. Minimal dose CT superior to chest X-ray for detection of recurrent lung cancer
9. Study reports adenoma detection rates are higher than current guidelines suggest in both men and women
10. Current HPV vaccine may not help some women with immune problems
11. Global burden of dengue is triple current estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The Smart ... unemployment—researchers from Oxford University predict that 47 percent of all jobs in the United ... redefining “smart” and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... October – December 2016 Revenues amounted to SEK 0.3 ... Result after tax amounted to SEK -16.3 (-6.5) million, corresponding ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... amounted to SEK -39.5 (-29.5) million Result after tax amounted ...
(Date:2/24/2017)... Ind. , Feb. 24, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the Cowen ... at the Boston Marriott Copley Place on Tuesday, March ... A live webcast of the presentation can be ... archived for replay following the conference via Zimmer Biomet,s ...
(Date:2/24/2017)... 24, 2017  In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to a ... internet on Tuesday, March 14, 2017 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
Breaking Medicine Technology: